Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 4/20 | 0.39 |
| ▸ | NRP1 | O14786 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337813 | 0.98 | GRB2 (0.44) | GRB2OPRD1OPRM1BDKRB2CMA1 | |
| SCHEMBL30744330 | 0.94 | GRB2 (0.41) | GRB2OPRD1OPRM1BDKRB2NRP1 | |
| SCHEMBL31197908 | 0.92 | APLNR (0.44) | GRB2BDKRB2ITGB3ITGA2BNTSR2 | |
| SCHEMBL29468832 | 0.91 | GRB2 (0.46) | GRB2OPRD1OPRM1BDKRB2NTSR2 | |
| SCHEMBL31197909 | 0.91 | GRB2 (0.45) | GRB2CMA1ITGB3ITGA2BNTSR2 | |
| SCHEMBL30744292 | 0.91 | APLNR (0.42) | GRB2OPRD1OPRM1CMA1ITGB3 | |
| SCHEMBL30423238 | 0.90 | GRB2 (0.46) | GRB2OPRD1OPRM1BDKRB2 | |
| SCHEMBL30543480 | 0.89 | GRB2 (0.46) | GRB2OPRD1OPRM1BDKRB2NTSR2 | |
| SCHEMBL29468766 | 0.88 | GRB2 (0.42) | GRB2OPRD1OPRM1BDKRB2CMA1 | |
| SCHEMBL30414346 | 0.87 | GRB2 (0.42) | GRB2OPRD1OPRM1BDKRB2CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589158-B2 | GLP-1/GIP dual agonist, preparation method and use thereof | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2026-03-31 | — | — | US | disclosed |
| US-20240325549-A1 | GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589158-B2 | GLP-1/GIP dual agonist, preparation method and use thereof | GLP1R, GIPR, IAPP | GRB2 761/4885OPRD1 108/4885OPRM1 205/4885 |
| US-20240325549-A1 | GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOF | GLP1R, GIPR, GCGR | GRB2 509/4885OPRD1 951/4885OPRM1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.